Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and 2-nitro-4-carboxyphenyl-n,n-diphenylcarbamate

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with 2-nitro-4-carboxyphenyl-n,n-diphenylcarbamate in 2 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Studies
(2-nitro-4-carboxyphenyl-n,n-diphenylcarbamate)
Trials
(2-nitro-4-carboxyphenyl-n,n-diphenylcarbamate)
Recent Studies (post-2010) (2-nitro-4-carboxyphenyl-n,n-diphenylcarbamate)
9,1561875523800

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Isono, K; Kondo, M; Nagai, A; Tagaya, E; Tamaoki, J; Yamawaki, I1
Durán, WN; Kim, DD; Ramírez, MM1

Other Studies

2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and 2-nitro-4-carboxyphenyl-n,n-diphenylcarbamate

ArticleYear
A human bronchial epithelial cell line releases arginine vasopressin: involvement of Ca2+ -activated K+ channels.
    Regulatory peptides, 1998, Jun-30, Volume: 74, Issue:2-3

    Topics: Arginine Vasopressin; Bradykinin; Bronchi; Carbamates; Cell Line; Epithelial Cells; Humans; Large-Conductance Calcium-Activated Potassium Channels; Peptides; Phenylcarbamates; Platelet Activating Factor; Potassium Channel Blockers; Potassium Channels, Calcium-Activated; Type C Phospholipases

1998
Platelet-activating factor modulates microvascular dynamics through phospholipase C in the hamster cheek pouch.
    Microvascular research, 2000, Volume: 59, Issue:1

    Topics: Administration, Topical; Animals; Arterioles; Biological Transport; Carbamates; Cheek; Cricetinae; Dose-Response Relationship, Drug; Enzyme Activation; Estrenes; Male; Mesocricetus; Microcirculation; Permeability; Phenylcarbamates; Phospholipases; Platelet Activating Factor; Pyrrolidinones; Type C Phospholipases; Vasoconstriction

2000